Promising strategies to overcome Th17 dysfunction in IBD might be represented by use of the natural/endogenous AhR ligands to improve immunosuppressive signalling via increased NTPDase1/CD39 expression. This evidence concerns the gene ENTPD1 and inflammatory bowel disease.